|Dr. Vuong Trieu Ph.D.||Exec. Chairman||N/A||N/A||54|
|Mr. Joseph W. Ramelli||CEO & Interim Pres||82.5k||N/A||49|
|Mr. Mihir Munsif||Chief Operating Officer||N/A||N/A||54|
|Dr. Michael V. Templin Ph.D., DABT||Chief Technology Officer||N/A||N/A||N/A|
|Dr. Larn Hwang Ph.D.||Chief Scientific Officer||N/A||N/A||54|
Marina Biotech, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company has three clinical development programs, such as IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication of familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. Its preclinical pipeline includes oligotherapeutics for the treatment of bladder cancer, inflammatory bowel, and duchenne muscular dystrophy diseases. The company is based in City of Industry, California.
Marina Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.